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Abstract WNT-5A plays critical roles in a myriad of
processes from embryonic morphogenesis to the mainte-
nance of post-natal homeostasis. WNT-5A knock-out
mice fail to survive and present extensive structural
malformations. WNT-5A predominantly activates b-cate-
nin-independent WNT signaling cascade but can also
activate b-catenin signaling to relay its diverse cellular
effects such as cell polarity, migration, proliferation, cell
survival, and immunomodulation. Moreover, aberrant
WNT-5A signaling is associated with several human
pathologies such as cancer, fibrosis, and inflammation.
Thus, owing to its diverse functions, WNT-5A is a crucial
signaling molecule currently under intense investigation
with efforts to not only delineate its signaling mechanisms
and functions in physiological and pathological condi-
tions, but also to develop strategies for its therapeutic
targeting.
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Introduction
WNT-5A is a member of the Wingless/integrase 1 (WNT)
family of secreted glycoproteins. In humans, 19 WNT
proteins (WNTs) are currently known that act as ligands for
several membrane-bound receptors which includes 10 class
Frizzled receptors (FZD), low-density lipoprotein receptor-
related protein (LRP) 5/6 co-receptors, and many non-class
FZD receptors, such as ROR1, ROR2, RYK, and PTK7 [1].
The intracellular WNT signaling is broadly classified into
two main branches—b-catenin-dependent (canonical) and
b-catenin-independent (non-canonical) WNT signaling.
Due to the complexity and vast diversity of downstream
signaling, the canonical and non-canonical nomenclature
has become outdated. WNT/b-catenin signaling is initiated
by binding of a WNT to a class FZD receptor and LRP5/6
co-receptors concluding a multimeric membrane signaling
complex which results in the stabilization and cytosolic
accumulation of transcriptional co-activator b-catenin.
Ultimately, the stabilized b-catenin translocates to the
nucleus where it associates with the T-cell factor/lymphoid
enhancer-binding factor (TCF/LEF) transcription factors
and activates WNT-target gene transcription [1]. In con-
trast, the b-catenin-independent signaling branches
function independent of b-catenin and LRP5/6 and activate
various signaling cascades involved in the regulation of
cell polarity and movements, cytoskeletal reorganization,
and gene transcription. Two of the best characterized b-
catenin-independent WNT signaling pathways are the
WNT/Ca2? and WNT/planar cell polarity (PCP) pathways.
The WNT/Ca2? signaling pathway involves activation of
Ca2?-dependent signaling molecules, including protein
kinase C (PKC), Ca2?/calmodulin-dependent protein
kinase II (CaMKII), and nuclear factor of activated T cell
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RhoA signaling or activation of c-Jun N-terminal Kinases
(JNKs) via small Rho-GTPases [2]. The WNT/Ca2? path-
way can also antagonize WNT/b-catenin signaling by
phosphorylation of TCF/LEF transcription factors via
activation of the TGF-b-activated kinase 1 (TAK1)-Nemo-
like Kinase (NLK) cascade [3].
WNT-5A, a prototypical WNT of b-catenin-independent
branch, is highly conserved among species and plays key
roles in the processes governing embryonic development,
post-natal tissue homeostasis, and pathological disorders
throughout the lifespan of an organism (Fig. 1) [4, 5].
Homozygous WNT-5A knock-out mice show perinatal
lethality, primarily due to respiratory failure, and present
extensive developmental abnormalities. It is involved in
lung [6], heart [7], and mammary gland morphogenesis [8]
and regulates stem cell renewal [9, 10], osteoblastogenesis
[11, 12], and tissue regeneration [13]. In addition, aberrant
WNT-5A expression and signaling is associated with var-
ious malignancies [14] and proinflammatory responses [15]
as well as with lung [16], renal [17], and hepatic [18]
fibrosis. WNT-5A signaling has also been implicated in
ciliopathies [19] and WNT-5A antagonism counteracts
vascular calcification [20]. We have recently reported
increased WNT-5A expression in asthmatic airway smooth
muscle cells [21] and have demonstrated that TGF-b
induces WNT-5A expression in airway smooth muscle
cells where it mediates expression of extracellular matrix
proteins (ECM) [21] and participates in airway remodeling
in asthma.
In view of the plethora of evidence associating WNT-5A
with health and disease, there is considerable interest in
understanding its biology. In this review, we discuss our
current understanding of various aspects of WNT-5A sig-
naling and its functions derived from studies in wide
variety of in vivo models including Drosophila, Xenopus,
and mouse; in vitro cell-based systems and patient-based
reports.
WNT-5A gene
WNT-5A cDNA was first isolated from mouse fetal tissue
[22] followed by the isolation and sequencing from human
cells [23]. The human WNT-5A gene is located on chro-
mosome 3p14-p21. The WNT-5A gene generates two very
identical transcripts by utilization of alternative transcrip-
tion start sites and the corresponding upstream sequences
are termed as promoter A and B [24] and their products as
WNT-5A-L and WNT-5A-S, respectively [25]. Both the
promoters have comparable transcriptional potential; their
activity, however, is highly context dependent. WNT-5A
promoter A has been suggested to be more active in human
and murine fibroblasts as compared to promoter B [26].
Both the isoforms have similar biochemical properties such
as stability, hydrophobicity, and signaling activity [25].
While the significance of individual WNT-5A isoforms is
not completely understood, and it is not entirely clear
whether they are functionally redundant, a recent study
showed that they might have different functions [25].
When ectopically expressed, WNT-5A-L inhibited prolif-
eration of various cancer cells lines, whereas WNT-5A-S
leads to stimulation of growth [25].
WNT-5A transcription
WNT-5A is a transcriptional target of an array of cytokines
and growth factors. CUTL1 [27], STAT3 [28], TBX1 [29],
and NFjB [30, 31] have been reported as transcription
factors for WNT-5A in various cell types. We have
recently shown that TGF-b induces expression of WNT-5A
by engaging p38 and JNK signaling via TAK1 in airway
smooth muscle cells [32]. This leads to the stabilization of
b-catenin which then interacts with Sp1. Sp1, in turn, binds
to the WNT-5A promoter and drives its expression [32].
TGF-b has also been shown to induce WNT-5A expression
in mammary glands [8], primary fibroblasts [8], primary
epithelial cells [8], and pancreatic cancer cells [27]. Sim-
ilarly, proinflammatory factors such as interleukin (IL)-1b
[31], tumor necrosis factor-a (TNF-a) [30], lipopolysac-
charide (LPS)/interferon c (IFNc) [15], IL-6 family
members-leukemia inhibitory factor (LIF) and car-
diotrophin-1 (CT-1) [33], and high extracellular calcium
concentration [34] all augment, whereas amino acid limi-
tation [35] represses WNT-5A expression in various cell
types. Collectively, this suggests that WNT-5A is a target
of TGF-b and proinflammatory signaling which will be
discussed below.
Interestingly, WNT-5A is also regulated at translational
level via the numerous AU-rich motifs which are present in
the evolutionary conserved 30-untranslated region of













Fig. 1 WNT-5A in health and disease. A schematic representation of
key functions and pathologies associated with WNT-5A
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binding proteins) associate with the AREs and tightly
regulate their stability by posttranscriptional mechanisms.
HuR, a member of embryonic lethal abnormal vision
(ELAV) -like family of ARE-binding proteins, binds to the
30-UTR AREs in WNT-5A mRNA and suppresses its
translation [36].
WNT-5A protein
WNT-5A-L and WNT-5A-S, composed of 380 and 365
amino acids, respectively, are heavily glycosylated and
lipid-modified proteins. Each isoform consists of an
N-terminal hydrophobic signal sequence, a conserved
asparagine-linked oligosaccharide consensus sequence and
about 22 highly conserved cysteine residues (Fig. 2a, b)
[23]. Cleavage of the N-terminal signal sequence is pre-
dicted to generate mature protein containing either 343 or
338 amino acids [25]. However, N-terminal sequencing of
mature WNT-5A isoforms revealed that WNT-5A-L is
cleaved after the 43rd amino acid, whereas WNT-5A-S has
much longer signal sequence with cleavage after the 46th
amino acid, generating mature proteins containing 337 and
319 amino acids, respectively (Fig. 2a, b) [25]. Interest-
ingly, mouse WNT-5A which is *99 % homologous to
human WNT-5A generates same mature protein as human
WNT-5A-S [37]. In mouse WNT-5A, asparagine 114, 120,
311, and 325 have been identified as the N-linked glyco-
sylation sites, whereas a palmitoylation has been identified
at cysteine 104. The palmitoylation of WNT-5A is neces-
sary for its binding to FZD5 and signaling activity but not
required for its secretion [38, 39]. In contrast, glycosylation
of WNT-5A is required for its secretion but dispensable for
its signaling activity [38].
WNT-5A: receptors and signaling
WNT-5A binding to receptor activates various b-catenin-
independent signaling cascades; however, it can also acti-
vate WNT/b-catenin signaling depending on the cell- and
receptor-context. WNT-5A can signal through multiple
receptors and according to current understanding FZD2,
FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, RYK, ROR2, and
CD146 may function as WNT-5A receptors [34, 37, 40–50].
WNT-5A has been shown to bind to FZD2 inducing
intracellular calcium release and PKC activation in Xeno-
pus [51] and zebrafish embryos [52] and WNT-5A-FZD2-
induced calcium spikes in neurons are implicated in trau-
matic brain injury [53]. WNT-5A binds to FZD2 in a
ROR1- or ROR2-dependent manner and recruits Dishev-
eled (DVL) and b-arrestin to FZD2 leading to the clathrin-
mediated internalization of FZD2 [40]. Internalization of
FZD2 is essential for WNT-5A-induced Rac activation
[40]. WNT-5A also induces clathrin-mediated internaliza-
tion of FZD4 [54] in a PKC- and b-arrestin-dependent
process and that of ROR2 in a PKC-dependent manner
[47]. Similarly, binding of WNT-5A to FZD5 also leads to
its internalization [38]. Internalization of receptors is con-
sidered as a critical step in WNT signaling and a reflection
of active signaling. Although the exact mechanisms
underlying the functional significance of receptor inter-
nalization are not clear, it is believed to facilitate
intracellular signaling activation by recruitment of scaf-
folding proteins such as b-arrestin and may also facilitate
the termination of signaling and receptor recycling [55].
We have recently demonstrated that WNT-5A signals
through FZD8 and RYK receptors leading to the activation
of Ca2?-NFATc1 and JNK signaling which mediates TGF-
b-induced ECM expression in airway smooth muscle cells
[21]. WNT-5A binding to FZD7 activates prosurvival
PI3K/AKT cascade in human melanoma cells which can
account for the resistance of these cells to BRAF inhibitors
[48]. Similarly, WNT-5A can activate the PI3K/AKT
cascade via FZD3 in human dermal fibroblasts and pro-
motes integrin-mediated adhesion of these cells [41]. In
contrast, WNT-5A-activated PI3K/AKT signaling induces
migration in human osteosarcoma cells [56]. Similarly,
WNT-5A induces migration in gastric cancer cells by
activating PI3K/AKT pathway which phosphorylates and
inactivates GSK-3b and activates RhoA leading to
cytoskeleton remodeling [57]. Indeed, cytoskeletal reor-
ganization and cell migration are major cellular effects of
WNT-5A signaling.
WNT-5A is proposed to regulate cell fate via FZD6 in
hair follicles [50], whereas it plays critical role in tuber-
culosis immunology via FZD5 regulating immune
responses by antigen presenting cells and activated T cells
in response to mycobacterium infection [42].
The FZDs belong to the class of seven transmembrane-
spanning G protein-coupled receptors. Recent evidence
shows a role for heterotrimeric G proteins in WNT-5A
downstream signaling. For instance, G proteins are
required for WNT-5A-induced JNK and NFjB activation
in human neutrophils [58]. Similarly, WNT-5A activates
Gai/o proteins leading to Ca
2?-dependent ERK1/2 activa-
tion in murine primary microglia [59] and HEK293 cells
[60]. A recent study has shown that Daple (DVL-associ-
ating protein with a high frequency of leucine residues)
functions as a non-receptor Guanine nucleotide exchange
factor in WNT signaling which interacts and activates Gai
in response to WNT-5A stimulation [61]. This indicates
that G protein coupling by FZDs is clearly a relevant
physiological phenomenon, but whether coupling with
heterotrimeric G proteins in FZD signaling is an absolute
requirement or context-dependent remains unclear [62].
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WNT-5A also binds to non-class FZD receptors
including ROR2 and RYK receptor tyrosine kinases. ROR2
is a key receptor for WNT-5A-induced effects during
development as demonstrated by remarkable phenotypic
resemblance between the ROR2 and WNT-5A knock-out
mice [63]. Multiple mechanisms have been suggested to
explain the close functional relationship between WNT-5A
and ROR2. WNT-5A interacts with ROR2 and VANGL2
to form a ternary complex leading to the casein kinase 1d
(CK1d)-induced phosphorylation of VANGL2 which
serves to relay the gradient effects of WNT-5A, thereby
regulating WNT-5A-induced planar cell polarity and
embryonic morphogenesis [64]. WNT-5A associates with
FZD7 in the presence of ROR2 to form a complex required
for DVL polymerization and activation of Rac-dependent
WNT signaling [49]. WNT-5A activates ERK1/2 in
intestinal epithelial cells via ROR2 [65], whereas it acti-
vates JNK-mediated c-Jun transcriptional activity to induce
production of receptor activator of nuclear factor-jB
(RANK), a regulator of osteoclast differentiation and
activation, in osteoclast precursor cells via ROR2 [11].
WNT-5A engages ROR2 to activate JNK signaling and
regulates cell movement [4, 66–68], whereas it induces
assembly of DVL-atypical PKC (aPKC) and polarity
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Fig. 2 WNT-5A protein. a A comparative analysis of amino acid
sequences of human WNT-5A-L and WNT-5A-S isoforms. Gray
highlighted area represents N-terminal signal sequence in respective
protein. Bold arrows mark the site of signal sequence cleavage and
N-terminus of respective mature protein. The amino acids marked in
red-bold represent posttranslational modification sites on protein
backbone. Number represents the respective position of the amino
acid from the first N-terminal amino acid. The protein sequences are
taken from NCBI: NP_003383.2 (WNT-5A-L) and NP_001243034.1
(WNT-5A-S). b Diagrammatic representation of WNT-5A-L protein.
N-terminal signal sequence is represented by blank box. represents
palmitoylation and represents N-linked glycosylation on the
protein backbone. The respective amino acids locations are marked
above the modification sites. The N-linked glycosylation sites N312
and N326 correspond to N311 and N325 of mouse WNT-5A,
respectively
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complex (PAR3 and PAR6) to regulate neuronal differen-
tiation and polarity [69, 70]. Thus, ROR2 participates in
several key cellular functions of WNT-5A.
WNT-5A activates intracellular calcium release to fine
tune neuronal growth by axonal outgrowth and repulsion.
WNT-5A signals via RYK leading to calcium release from
stores through IP3 receptors as well as calcium influx
through transient receptor potential (TRP) channels
inducing axonal outgrowth. On the other hand, simultane-
ous association of WNT-5A with RYK and FZD releases
calcium from TRP channels without involvement of IP3
receptors and induces axonal repulsion [71]. WNT-5A also
forms a ternary complex with RYK and VANGL2 to relay
the WNT/PCP effects [72], whereas WNT-5A-RYK sig-
naling is required for inhibition of reactive oxygen species
(ROS) production and maintenance of hematopoietic stem
cell quiescence [73].
Recently, WNT-5A binding to an adhesion molecule
CD146 has also been described, leading to the recruitment
of DVL2 to the complex and activation of downstream
JNK signaling cascade [45]. CD146 has been linked to cell
migration via RhoA-dependent cytoskeletal rearrange-
ments [74]. In line with that, WNT-5A-CD146 axis
regulates polarity and migration of cells [45, 75].
Effects of WNT-5A on b-catenin signaling
Interestingly, in addition to activating the b-catenin-inde-
pendent WNT pathway, WNT-5A can also have positive or
negative regulatory effects on WNT/b-catenin signaling
depending on the receptor- and cell-context. Indeed, a
study has shown that WNT-5A can both activate and
inhibit b-catenin-dependent WNT signaling during mouse
embryonic development [76]. WNT-5A knock-out
embryos show increased b-catenin activation in telen-
cephalon and embryonic fibroblasts from WNT-5A knock-
out animals show heightened response to WNT3A, a pro-
totypical b-catenin-dependent signaling WNT [40].
Another study demonstrated that WNT-5A competes with
WNT-3A for binding to FZD2, a receptor for both the
WNTs, thereby inhibiting the WNT-3A-induced b-catenin
signaling [40]. The WNT-5A-activated CaMKII–TAK1–
NLK1 cascade has been implicated in WNT/b-catenin
suppression [3]. In addition, WNT-5A inhibits WNT-3A-
induced b-catenin signaling via ROR2 and CD146 [37, 45].
In hematopoietic stem cells, WNT-5A inhibits b-catenin
signaling supposedly via suppression of ROS production
[73]. Similarly, WNT-5A inhibits b-catenin signaling by
promoting its degradation through an alternative E3 ubiq-
uitin ligase complex composed of siah2-APC-Ebi [77].
Purified WNT-5A, on the other hand, can activate b-cate-
nin-dependent transcription in the presence of FZD4 and
LRP5 [37, 46]. Also, WNT-5A activates b-catenin signal-
ing in pancreatic cancer cells [27, 78] and dermal
fibroblasts [79]. Similarly, osteoblast-lineage cells from
WNT-5A knock-out mice show reduced WNT/b-catenin
signaling and WNT-5A pre-treatment potentiated the
WNT/b-catenin signaling in bone marrow stromal cells via
upregulation of LRP5 and LRP6 expression [80].
Functions of WNT-5A
Embryogenesis
WNT-5A has been identified for its key involvement in
defining the body outgrowths in addition to many other
specific features. WNT-5A expression is most abundant
during early embryonic developmental stages between
10–14 days post conception [5, 22]. Importantly,
homozygous WNT-5A knock-out mouse embryos show
perinatal lethality underlining its vital role in embryogen-
esis. During development, regions undergoing extensive
outgrowth like limbs, tail, and facial structures exhibit
prominent WNT-5A expression where it is present in a
graded fashion with the highest abundance at the tips of
these structures and lowest in the proximal areas [5, 22].
WNT-5A knock-out leads to severe malformations in the
outgrowth structures, a shortened anterior–posterior (A–P)
and severely compromised proximal–distal (P–D) body
axis. These malformations could be traced back to the
underlying axial skeleton which exhibited a shortened
vertebral column due to smaller vertebrae size and the
absence of caudal vertebrae. The phenotype apparently
originates from the critical role of WNT-5A as a mitogen
required for the proliferation of the mesodermal progeni-
tors early in embryonic development. The mesodermal
stem cells which arise early in development can continue to
develop in the primitive streak even in the absence of
WNT-5A but lack the ability to divide and give rise to the
progeny. Impaired self-renewal capacity leads to progres-
sive depletion of the stock of these stem cells resulting in
insufficient numbers of cells to develop the distal skeleton
and leading to the absence of related structures [5].
Similar to WNT-5A knock-out mice, WNT-5A trans-
genic mice show perinatal lethality when WNT-5A is
induced early in development exhibiting severe deformities
resembling the WNT-5A knock-out phenotype [81].
Overexpression of WNT-5A induced malformations of
limbs, tail, and facial structures. Underdeveloped limb
skeletal elements, reduced number of tail vertebrae, and
shortened upper and lower jaw bones constituted the
mutant phenotype. Interestingly, overexpression of WNT-
5A in later embryonic stages and in adult animals was well
tolerated with no visible phenotype [81]. This study
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highlights a critical window during embryonic develop-
ment when WNT-5A activity is most required [81].
Further studies have looked into the organ-specific
developmental roles of WNT-5A and have identified a
crucial role for distal morphogenesis of internal organs. For
instance, WNT-5A knock-out mice fail to develop the
genital tubercle [5] and have intestinal deformities [82].
Prominent WNT-5A expression is observed in the gut
mesenchyme during intestinal morphogenesis which per-
sists throughout the development of the small intestine [5,
83]. In line with that, WNT-5A knock-out mice show
severe malformations in the small intestine with drastically
reduced length and the presence of a secondary cavity. In
addition, the mutants present an imperforated anus [82].
Interestingly, overexpression of WNT-5A during embry-
onic development also leads to gut malformations
resembling the WNT-5A knock-out phenotype. Specifi-
cally, WNT-5A transgenic mice show shortening of the
small and large intestine, caecum, and stomach and also
present anal imperforation [81]. Of note, both the loss and
overexpression of WNT-5A does not interfere with the
intestinal differentiation or cell fate decisions. The under-
lying mechanisms that lead to the malformations observed
in WNT-5A transgenic mice are not clear yet. However,
the observation that overexpression of WNT-5A leads to
the downregulation of ROR2 in intestine [81] could reveal
the reason behind the similarities in both the WNT-5A
transgenic and knock-out phenotypes. ROR2 is a receptor
for WNT-5A and ROR2 knock-out mice show a phenotype
resembling that of WNT-5A knock-out [63]. Therefore,
increased expression of WNT-5A which leads to the
downregulation of ROR2 could present a similar phenotype
as ROR2 knock-out. Although the downstream WNT-5A
signaling after overexpression remained intact, it is
tempting to speculate that ROR2-dependent WNT-5A
signaling is crucial for the embryonic development and that
the loss of ROR2 in WNT-5A transgenic mice underlies
the similarity with the WNT-5A knock-out phenotype.
Convergent extension (CE) is the critical morphogenetic
movement during gastrulation wherein the germ layers
narrow down mediolaterally resulting in the elongation of
embryo from head to tail and shaping of body axis [84]. CE
requires collective cell migration and cell intercalations.
WNT-5A-activated signaling has been associated with CE
movements [85–87] owing to its ability to regulate cell
migration and polarity (as discussed in this review). Thus,
embryonic structural abnormalities in WNT-5A knock-out
and transgenic mice may not only arise from impaired
proliferation but also due to derailed CE movements.
Lungs are complex organs with extensive branching, a
large number of different types of specialized cells, and
distinct P–D polarity. WNT-5A, as a major determinant of
P–D polarity, is prominently expressed in the embryonic
lungs [6, 22] where it is localized in both the mesenchymal
and epithelial compartments. WNT-5A signaling is most
enhanced at the tip and around the branching epithelium
[6]. In later stages, WNT-5A is predominantly localized to
the lung epithelium and attains a typical P–D gradient with
most expression in the distal branching epithelium and
almost no presence in the proximal regions [6]. Analysis of
lungs obtained from WNT-5A knock-out mice revealed
extensive developmental malformations. The trachea was
truncated with reduced number of cartilages [6]. The
branching morphogenesis of WNT-5A knock-out lungs
was compromised as revealed by the increased number and
overexpansion of terminal airways. Also, the intersaccular
walls were thick and hypercellular indicating failed matu-
ration of lungs in WNT-5A knock-out embryos. Further
analysis revealed that loss of WNT-5A did not interfere
with cell differentiation but led to hyperproliferation
resulting in intersaccular septum thickening and disrupted
vasculature [6]. Interestingly, WNT-5A knock-out lungs
presented increased expression of sonic hedgehog/patched
(SHH/PTC), fibroblast growth factor (FGF), and bone
morphogenetic protein(BMP)-4 indicating the molecular
mechanisms involved in the observed WNT-5A knock-out
phenotype [6]. Notably, lungs of WNT-5A knock-out mice
show resemblance with the FGF-10 knock-out [88], SHH
knock-out [89, 90], SHH transgenic [91], and BMP-4
transgenic [92] lung phenotype, which underlines the
interactive network of WNT-5A, FGF-10, SHH/PTC, and
BMP-4 in lung development. Lung-specific WNT-5A
transgenic expression also disrupts lung morphogenesis as
demonstrated by dilated terminal airways, loss of branch-
ing, and smaller size of the lungs [93]. Interestingly,
supporting a role for WNT-5A in regulating other signaling
cascades, WNT-5A overexpression repressed SHH/PTC
expression and distribution in the lung epithelium, whereas
it augmented FGF-10 abundance in the mesenchyme [93].
While FGF-10 expression is increased, WNT-5A overex-
pression severely impairs the ability of epithelium to
respond to FGF-10 [93]. Thus, WNT-5A fine-tunes the
developmental signaling underlying the epithelial-mes-
enchyme communication which is required for proper lung
morphogenesis [93].
WNT-5A expression is crucial for proper neuronal
generation and axonal guidance during embryonic devel-
opment and in post-natal life. WNT-5A knock-out mice
show anomalies in the dopaminergic midbrain neuronal
morphogenesis, organ innervation, and show increased
neuronal apoptosis [94, 95]. Robust WNT-5A expression is
detected in ventral midbrain where it promotes dopamin-
ergic neurite and axonal growth [95]. In fact, WNT-5A
promotes and cooperates with WNT/b-catenin signaling to
generate midbrain dopaminergic neurons in vivo and in
stem cells [39, 96], whereas WNT-5A expression in the
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sympathetic neurons is crucial for axonal branching for
proper organ innervation via ROR1 and ROR2 receptors
[63, 94]. WNT-5A can also signal via RYK to mediate
cortical axonal growth and guidance [43, 71]. The absence
of axonal guidance in both the ROR1/2- and RYK-deficient
mice shows their function is non-redundant and the uti-
lization of respective receptors may be context dependent.
WNT-5A is also required for proper cardiac morpho-
genesis as WNT-5A knock-out mice show severe defects in
the septation of the cardiac outflow tract (OFT) [97]. OFT
originates from an embryonic region called second heart
field (SHF) which functions as a source of progenitor cells
for development of most of the heart. WNT-5A is
expressed in the pharyngeal mesoderm adjacent to cardiac
neural crest cells in both mouse and chicken embryos and
in the myocardial cell layer [97]. WNT-5A expression is
induced in SHF by a transcription factor-TBX1 and loss of
WNT-5A results in severe decline in the number of SHF
progenitor cells and deployment of these progenitors to the
OFT leading to cardiac deformities [7, 29, 98].
In summary, WNT-5A signaling is crucial to the
development of internal organs and the formation of
skeletal structures. Of importance, WNT-5A cooperates
with other WNTs (e.g., WNT-11) and several non-WNT
morphogens involved in development including TGF-b,
BMPs, FGFs, and SHH signaling [8, 93, 99, 100]. This
cooperation is essential, and while removing WNT-5A
from this signaling network may lead to severe embryonic
phenotypes, these phenotypes may not be attributed to
WNT-5A alone. An intriguing example is the close coop-
erativity of WNT-5A and WNT-11 in the development of
the second heart field in mice. Here, WNT-5A and WNT-
11 are both required in suppressing WNT/b-catenin sig-
naling in progenitors in the developing heart to allow for
differentiation [7]. Recently, it was shown that WNT-5A
and WNT-11 cooperate to regulate convergent extension
movements leading to A–P axis formation in mice [101].
However, mice lacking WNT-5A (and not WNT-11) show
severe A–P axis shortening and limb truncations high-
lighting a redundant role for WNT-11 in this process [5,
101, 102]. Clearly, WNT-5A is an essential component in
the machinery that governs embryogenesis, and signaling
by WNT-5A is non-redundant with that of other b-catenin-
independent signaling WNTs.
Migration
Cell migration requires acquisition of new asymmetry and
polarity along with reorganization of the cytoskeleton and
breaking and/or reprocessing cell–cell and cell–substrate
adhesions. As such, the WNT/PCP and WNT/Ca2? path-
ways have been linked with migration of cells. Several
studies have elucidated the significance and molecular
mechanisms of WNT-5A-induced cell migration (Fig. 3).
For instance, a study has identified the WNT-5A-ROR2
axis in regulating cell motility. WNT-5A interacts with
ROR2 and induces its association with Filamin A, an actin
binding protein, which, in turn, leads to formation of
filopodia [103]. Filopodia are actin-based structures pro-
jecting at the leading edge of migrating cells and are
important in formation of focal adhesions attaching to the
substrate and facilitating directional cell movement [104].
WNT-5A-induced ROR2-Filamin A association activates
aPKC which in turn activates JNK. Activated JNK may
mediate cell migration by microtubule organizing center
(MTOC) reorientation and actin remodeling via phospho-
rylation and activation of CapZ-interacting protein
(CapZIP) [105]. In addition, JNK can also phosphorylate
paxillin regulating focal adhesion complexes [106, 107]
and modulating cell motility in response to WNT-5A. In
another mechanism, WNT-5A induces cell migration via
Daple-mediated Rac activation [108]. Daple interacts with
DVL in response to WNT-5A and facilitates its interaction
with aPKC consequently inducing Rac activation. This
leads to cytoskeletal reorganization promoting lamellipodia
formation and cell migration [108]. In addition to aPKC,
WNT-5A can also employ Rab35 to activate Rac in a
DVL-dependent manner and induce cell migration [109].
The WNT-5A-RhoA axis has been prominently linked
with cytoskeletal remodeling and cell motility in various
cell systems. WNT-5A induces RhoA activation via DVL
and Daam1 in breast cancer cells [110] or via PI3K/AKT
signaling in gastric cancer cells [57]. Activated RhoA, in
turn, may engage other downstream pathways such as JNK
to mediate WNT-5A-induced cell migration [67].
CD146, an adhesion molecule, can also activate RhoA
and has been shown to be involved in cell migration [74].
Interestingly, WNT-5A induces redistribution of CD146
and accumulation of a unique membrane complex com-
posed of actin, myosin IIB, and FZD3 (termed W-RAMP)
asymmetrically at the cell periphery in a DVL- and PKC-
dependent manner in melanoma cells [75]. This complex,
in turn, initiates directional movement and requires RhoB-
and Rab4-mediated membrane internalization and endo-
somal trafficking [75]. Of note, the cell movements in this
context were RhoA independent. A recent study, on the
other hand, has shown that WNT-5A directly binds to
CD146 to activate DVL leading to activation of JNK
thereby promoting formation of cell protrusions and cell
migration [45]. Whether WNT-5A employs RhoA or the
membrane complex-W-RAMP, for JNK activation down-
stream of CD146 is not clear.
Besides non-canonical WNT signaling, WNT-5A can
also activate b-catenin-dependent signaling to promote cell
migration. In melanoma cells, WNT-5A activates small
GTPase ADP-ribosylation factor 6 (ARF6) via FZD4-LRP6
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binding. ARF6 releases membrane-bound b-catenin from
N-cadherin increasing its cytosolic abundance and trig-
gering b-catenin-dependent transcriptional program that
induces invasion and metastasis [46].
WNT-5A can also alter the adhesion properties of cells
to regulate migration. For instance, WNT-5A binding to
FZD3 activates the PI3K/AKT cascade in human dermal
fibroblasts and promotes integrin-mediated adhesion of
these cells [41].
Thus, WNT-5A exerts migratory effects in large number
of cell and tissue types in physiological and pathological
contexts.
Stem cell differentiation and regeneration
Owing to its property of regulating cell polarity, cell
movement, and cell proliferation along with the antago-
nistic effects on WNT/b-catenin signaling, WNT-5A may
play a critical role in modulating cell fate determination
and differentiation of stem cells.
Hematopoietic stem cells exhibit a shift from b-catenin-
dependent to -independent WNT signaling with aging
where high levels of WNT-5A are present in aged stem
cells [10]. Interestingly, treatment of young hematopoietic
stem cells with WNT-5A induces age-related changes such
as aging-associated stem cell apolarity, reduced regenera-
tive capacity, and an aging-like myeloid–lymphoid
differentiation shift via activation of small Rho GTPase
CDC42 [10]. On the other hand, reduction of WNT-5A
expression in aged hematopoietic stem cells leads to their
functional rejuvenation [10]. Moreover, effects of WNT-
5A as observed in this study are dependent on the cell-
intrinsic WNT-5A abundance and not on WNT-5A levels
in stromal cells [10]. It is interesting to note that WNT-5A
negatively regulates hematopoietic stem cell differentiation
via inhibition of WNT/b-catenin and NFAT signaling
thereby maintaining them in a quiescent stage and pro-
moting their repopulation [73, 111, 112]. This effect is
mediated by RYK-dependent inhibition of endogenous
reactive oxygen species (ROS) generation [73].
Similarly, WNT-5A is also critical in mesenchymal
stem cell (MSC) biology. MSCs can differentiate into
multiple cell types such as adipocytes and osteocytes.
Higher expression of WNT-5A is detected in MSCs as
compared to committed preadipocytes which can only give
rise to adipocytes [113]. Interestingly, depletion of WNT-
5A in MSCs leads to their commitment to adipocytes and



























































Fig. 3 WNT-5A-activated signaling cascades in cell migration.
Diagrammatic representation of few key signaling cascades engaged
by WNT-5A to regulate actin cytoskeletal remodeling and cell
migration. ARF6 ADP-ribosylation factor 6, GEF100 ARF-guanine
nucleotide exchange protein 100, FlnA filamin A, aPKC atypical
protein kinase C, JNK c-Jun N-terminal protein kinase, CapZIP
CapZ-interacting protein, DVL disheveled, Daam1 DVL-associated
activator of morphogenesis 1, Daple DVL-associating protein with a
high frequency of leucine residues, ROCK rho-associated kinase,
LRP6 low-density lipoprotein receptor-related protein 6, G G pro-
teins, [Ca2?]i intracellular calcium release
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WNT-5A is critical for the regulation of differentiation and
lineage commitment of MSCs [113]. Indeed, the presence
of WNT-5A in human bone marrow MSC inhibits adipo-
genesis and promotes osteoblastogenesis by inhibition of
peroxisome proliferator-activated receptors c (PPARc)
transactivation via a CaMKII-TAK1-TAK1-binding pro-
tein2 (TAB 2)-NLK signaling axis and simultaneous
induction of runt-related transcription factor (RUNX)
expression [114]. PPARc activation is required for adipo-
genesis, whereas RUNX2 is critical for osteogenesis [115].
Interestingly, WNT-5A-activated PKC and ROCK signal-
ing can also induce osteogenic differentiation in adipose-
tissue-derived mesenchymal stromal cells [116]. Thus,
WNT-5A functions as a master regulator determining MSC
differentiation into osteogenic or adipogenic lineages.
In line with its role in morphogenesis and stem cell
differentiation, WNT-5A has recently been shown to be
involved in tissue repair and regeneration after injury. A
study demonstrated robust induction of WNT-5A-positive
mesenchymal cells following an intestinal injury which are
specifically localized in the wound bed [13]. The presence
of WNT-5A provided a demarcation of the regenerating
proliferative area via potentiation of TGF-b signaling. This
allowed a fine-tuning of regeneration and proper wound
healing [13]. Increased amount of WNT-5A is observed in
lung tissue from mouse model of acute respiratory distress
syndrome (ARDS) which could be the repair response of
damaged lungs to resolve the injury [117]. Indeed, WNT-
5A can promote the survival of bone marrow derived
MSCs following an oxidative-stress injury and can induce
their differentiation into the type II alveolar epithelial cells
via activation of JNK and PKC signaling [117].
WNT-5A also regulates spermatogenesis by supporting
self-renewal and survival of spermatogonial stem cells
(SSC) [9]. In contrast to hematopoietic stem cells and
MSCs, SSCs do not express WNT-5A but its receptors—
FZD3, FZD5, FZD7, and ROR2. Interestingly, WNT-5A is
expressed and provided by the testicular stromal popula-
tion—sertoli cells, where it promotes SSC maintenance and
activity by inhibiting apoptosis in JNK-dependent manner
[9].
Thus, WNT-5A may exert a highly context-dependent
cell-intrinsic and -extrinsic effects in regulation of stem
cell biology, regeneration, and repair.
WNT-5A in disease
Consistent with the broad functional effects of WNT-5A
during embryonic and adult life, disrupted WNT-5A sig-
naling leads to the development of various pathological
conditions in humans. We here summarize the role of
WNT-5A in human pathologies such as fibrosis, inflam-
mation, and cancer.
Fibrosis
WNT-5A mRNA and protein expression is increased in
fibroblasts obtained from lungs of usual interstitial pneu-
monia (UIP) patients [16]. Similarly, increased WNT-5A
expression is detected in lungs following mechanical
ventilation where it participates in the mechanical venti-
lation-induced pulmonary fibrosis [118]. WNT-5A is also
present in high abundance in BAL fluid of sarcoidosis
patients [119]. Augmented levels of WNT-5A are also
detected in the dermal fibroblasts from keloids [120],
whereas WNT-5A expression is identified in the fibrotic
areas of affected human liver [121] and found increased
in liver tissues from mouse model of liver fibrosis [18,
122].
Activated hepatic stellate cells (HSCs) are keys to the
development of fibrotic liver by contributing the extra-
cellular matrix (ECM) and other fibrotic factors. WNT-5A
is particularly enriched in the ECM deposited by activated
HSCs [121] which express more WNT-5A than the qui-
escent HSCs [18, 122] and normal human fibroblasts
[121].
Fibroblasts from pulmonary fibrosis patients and keloid
regions show increased proliferation, survival, and
expression of ECM proteins [123, 124]. WNT-5A engages
cAMP-PKA-CREB and PKA-GSK-3b-b-catenin pathways
in dermal fibroblasts protecting them from apoptosis [79].
In line with these observations, WNT-5A promotes pro-
liferation and survival of lung fibroblasts and also
augments fibronectin and integrin expression [16]. Simi-
larly, WNT-5A drives proliferation of and ECM
deposition by activated HSCs [18]. Tissue fibrosis is an
important feature of airway remodeling in obstructive
lung diseases such as asthma and chronic obstructive
pulmonary disease (COPD) in which airway smooth
muscle can play a critical role. We have recently identi-
fied a role for WNT-5A in TGF-b-induced ECM
expression in airway smooth muscle cells [21]. WNT-5A
is a target of TGF-b in airway smooth muscle cells where
it engages b-catenin-independent WNT signaling activat-
ing Ca2?-NFAT and JNK to induce ECM expression [21].
While TGF-b can regulate WNT-5A expression in airway
smooth muscle cells, WNT-5A regulates expression of
TGF-b in HSCs [18] underlining a critical profibrotic axis
in fibrotic disorders.
In contrast of its profibrotic role, WNT-5A may be
protective in diabetic renal nephropathy. High-glucose
suppresses WNT-5A expression among other WNTs and
promotes expression of fibrotic markers via TGF-b
[125]. Forced expression or presence of recombinant
WNT-5A inactivates GSK-3b thereby stabilizing b-
catenin and counteracts high-glucose-induced fibrotic
effects [125].
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Inflammation
WNT-5A is associated with several inflammatory disorders
where it not only mediates proinflammatory cytokine and
chemokine production but also regulates migration and
recruitment of various immune effector cells.
Microbial pathogens [42, 126] and several proinflam-
matory factors such as IL-1b [31], TNF-a [30], LPS/IFNc
[15], and the IL-6 family members LIF and CT-1 [33]
induce WNT-5A expression in various cell types high-
lighting a critical role for WNT-5A in immune responses.
Abundant expression of WNT-5A is detected in the gran-
ulomatous lesions in the Mycobacterium tuberculosis-
infected lungs [42], in the chronic periodontitis tissue
[127], sera and bone marrow macrophages of patients with
severe sepsis [15], the atherosclerotic lesions in humans
and mouse [128], in human dental pulpitis tissues [129], in
circulation and visceral fat tissues of obese patients [130],
and in the synovial tissue and synovial fibrobalsts from
rheumatoid arthritis patients [30, 131].
WNT-5A is associated with the maintenance of innate
immune responses both in homeostasis and pathology.
Basal WNT-5A expression by macrophages drives static
IFN-b and -c expression via a Rac1-NFjB pathway and
also regulates expression of CD14 which is required for
antigen recognition and innate immune responses during
infection [132]. In addition, basal WNT-5A signaling also
supports survival of macrophages as loss of WNT-5A
decreases expression of prosurvival genes such as BCL-2,
BCL-xl, and MCL-1, with a concomitant increase in
expression of Bax, a proapoptotic protein [132]. Thus,
WNT-5A is suggested to contribute to the immune system
readiness for countering any future infection. Pathogenic
signals such as microbes or microbial products (i.e., LPS)
induce expression of WNT-5A which mediates the release
of proinflammatory factors such as TNF-a, IL-6, and
interferons from macrophages [132]. In addition, WNT-5A
also promotes phagocytosis of microbes in a PI3K-Rac1-
dependent manner. Interestingly, WNT-5A does not influ-
ence bacterial killing inside the phagosome prolonging
presence of the antigen and as such might contribute to the
development of sepsis by supporting sustenance of the
microbial infection and persistence of proinflammatory
macrophages at the site of infection [133].
WNT-5A also contributes to the immune responses by
regulating the differentiation of T cells [42]. Mycobac-
terium infection or the presence of LPS induces WNT-5A
expression in human antigen presenting cells and T cells in
a TLR-NFjB-dependent manner where it mediates
expression of IL-12 and IFNc [42] contributing to the
antimicrobial defense. TLR-4–MyD88 signaling is also
associated with downstream effects of WNT-5A to induce
expression of IL-12p40 and IL-6 in primary macrophages
[134]. Similarly, LPS/IFNc induces WNT-5A expression
in macrophages where it activates CaMKII and mediates
the release of IL-1b, IL-6, IL-8, and MIP1b [15].
Neutrophil recruitment to the region of infection or site
of injury under the influence of various chemoattractants is
another key event in innate immune response, whereas
excessive neutrophilic inflammation has been linked to
various diseases such as asthma and COPD. Human neu-
trophils express several WNT-5A receptors such as FZD2,
FZD5, and FZD8 and treatment with WNT-5A induces the
release of IL-8 and CCL2 via MAPK signaling, promoting
neutrophil migration [58]. CCL2 is an important neutrophil
chemoattractant and is also contributed by the macro-
phages. WNT-5A upregulates CCL2 expression in
macrophages via JNK and NFjB signaling [135] and
supernatants from LPS-treated macrophages effectively
induce neutrophil migration via WNT-5A [58] emphasiz-
ing an important macrophage-neutrophil cross-talk
mediated by WNT-5A.
WNT-5A has come under intense scrutiny for its role in
neuroinflammatory disorders. WNT-5A induces upregula-
tion of cyclooxygenase-2 (COX-2) expression and
production of proinflammatory cytokines IL-1b, IL-6, and
TNF-a in primary microglia [59]. It has also been associ-
ated with the Alzheimer’s disease-linked
neuroinflammation. b-Amyloid peptide (Ab) induces
expression of WNT-5A in primary cortical neurons where
it activates NFjB via upregulation of NF-jB-inducing
kinase (NIK) and mediates expression of IL-1b [136].
WNT-5A-mediated Ab-induced neuroinflammation is
suggested to contribute to the neurotoxicity and Alzhei-
mer’s disease-related neural degeneration [136].
The proinflammatory functions of WNT-5A are not only
restricted to the immune cells. In human adipocytes, WNT-
5A induces IL-6 and IL-1b expression [130]. In bone
marrow stromal cells, LPS induces WNT-5A where it
regulates expression of a plethora of proinflammatory
cytokines in a MAPK- and NFjB-dependent signaling and
promotes chemotactic migration of monocytes and T cell
indicating a possible role in pathophysiology of rheumatoid
arthritis [30]. In endothelial cells, WNT-5A augments
COX-2 expression and proinflammatory cytokine produc-
tion via the Ca2?-PKC-NFjB axis and increases vascular
permeability and endothelial cell migration [137]. WNT-
5A expression is induced in human dental pulp cells fol-
lowing TNF-a stimulation where it regulates IL-8 and
CCL2 expression via a MAPK and NFjB signaling cas-
cade and influences macrophage migration [129].
In contrast to the proinflammatory role, WNT-5A can
also have opposing effect on inflammation. It has been
shown to negatively regulate LPS-induced inflammatory
responses in microglia by inhibiting COX-2 upregulation
[138]. Another study showed that WNT-5A could function
576 K. Kumawat, R. Gosens
123
as anti-inflammatory factor by suppressing the proinflam-
matory M1 phenotype of macrophages in the presence of
LPS/IFNc [139] thus limiting the inflammation in various
pathological situations. A dose-dependent interaction
between WNT-5A and LPS could explain this discrepancy
as different doses of LPS elicit differential WNT-5A
responses by macrophages. It is quite plausible that low
doses of LPS support proinflammatory function of WNT-
5A, whereas at high LPS doses WNT-5A induces a
tolerogenic phenotype in macrophages [133] thereby sup-
pressing inflammation.
Cancer
WNT/b-catenin signaling is closely associated with
malignant disorders [140]. WNT-5A, owing to its proper-
ties of both activating and inhibiting WNT/b-catenin
signaling and regulating cell movements, can be linked
with cancer pathobiology. Studies have proposed both pro-
and anti-tumor functions for WNT-5A and have identified
several underlying signaling cascades (Table 1). Low or
loss of expression of WNT-5A is linked to increased
metastatic and invasive phenotype and poor prognosis in
breast and colorectal cancers, whereas in thyroid cancer, it
may have tumor-suppressor activity despite its increased
expression [141–144]. Likewise, deletion or loss of WNT-
5A expression is observed in human B cell lymphomas and
myeloid leukemias [145]. On the other hand, strong
expression of WNT-5A is shown in prostate cancer, acute
T-cell leukemia, melanomas, and non-melanomas where it
correlates with cell motility and tumor invasiveness [146–
151].
Aberrant expression of components of b-catenin-inde-
pendent pathway, WNT/PCP, has also been reported in
Chronic lymphocytic leukemia (CLL) [152]. The study
showed that WNT-5A, which is also expressed in the CLL
cells, promotes polarized cell migration towards chemo-
kine gradient (CXCL10, CXCL11, CXCL12, and CCL21)
in CK1-dependent manner [152]. In another example, high
expression of WNT-5A is observed in the PBMCs derived
from acute T-cell leukemia/lymphoma (ATL) patients
[151]. Due to its effects on osteoclast differentiation [151],
WNT-5A may drive osteolytic bone lesions and hypercal-
cemia which are the major complications in ATL patients
[153, 154].
In contrast to CLL and ATL, WNT-5A may have tumor
suppressive effects in ALL. Loss of WNT-5A expression is
reported in acute myeloid and acute lymphoblast leukemia
[145]. WNT-5A has been shown to be epigenetically
silenced by promoter hypermethylation in acute lymphoblast
leukemia cells leading to the loss of expression which may
drive unrestricted B cell proliferation and malignant devel-
opment [155]. Indeed, WNT-5A heterozygous mice develop
spontaneous B cell malignancies underlining the tumor
suppressive role of WNT-5A [145].
Similarly, WNT-5A promoter hypermethylation is also
observed in the esophageal squamous cell carcinoma
(ESCC) tissues [156]. Ectopic expression of WNT-5A led
to reduction in b-catenin signaling and inhibition of
clonogenicity and motility in ESCC cell lines suggesting
the tumor suppressive role of WNT-5A in ESCC [156].
WNT-5A expression is highly increased in gastric can-
cer and positively associates with tumor invasiveness,
metastasis, and survival of the patients [157]. Administra-
tion of anti-WNT-5A antibody attenuates liver metastases
of gastric cancer cells in vivo [158]. WNT-5A employs
several mechanisms to regulate gastric cell invasiveness
such as activation of focal adhesion kinase and Rac1 to
regulate turnover of paxillin-containing adhesions [157],
activation of PI3K/AKT pathway to regulate actin stress
fiber formation [57], and activation of JNK and PKC sig-
naling to induce Laminin c2 [159] promoting cell
migration. Additionally, WNT-5A abundance correlates
with the expression of MCP-1 and IL-1b in gastric cancer
tissues indicating that WNT-5A may drive macrophage
infiltration and tumor-related inflammation [160].
WNT-5A expression is highly increased in non-small
cell lung cancer (NSCLC) and has been associated with
poor prognosis [161, 162]. Tobacco smoke is a very potent
inducer of lung cancer [163] and exposure to cigarette
smoke-extract induces WNT-5A expression in human
bronchial epithelial cells [164]. WNT-5A activates PKC to
upregulate anti-apoptotic genes such as BCL-2 in these
cells thereby protecting them from death explaining the
tumorigenic properties of WNT-5A [164].
Extensive WNT-5A expression is detected in human
melanoma biopsies where it correlates with the formation
of distant metastases and poor prognosis [148, 150]. WNT-
5A strongly induces cell migration and invasion of mela-
noma cells, possibly, by inducing epithelial-to-
mesenchymal transition (EMT) while decreasing the
expression of metastatic suppressors [150, 165]. IL-6
induces WNT-5A in melanoma cells via p38 which, in
turn, mediates cell migration [166]. As discussed earlier,
WNT-5A activates ARF6 in melanoma cells leading to
disruption of N-cadherin-b-catenin interaction, enhanced
b-catenin-mediated transcription and invasion [46]. It can
also activate Ca2?-dependent signaling leading to the
activation of calpain protease which cleaves filamin A.
Cleavage of filamin A induces cytoskeletal remodeling and
cell motility [167]. WNT-5A can also confer a survival
advantage to melanoma cells, thereby negatively influ-
encing the outcome of therapeutic approaches. Prolonged
treatment with BRAF inhibitors induces WNT-5A
expression in melanoma cells and contributes to the
development of resistance to BRAF inhibitor-induced
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apoptosis [48]. This process involves FZD7- and RYK-
mediated activation of prosurvival AKT signaling [48].
Knock-down of endogenous WNT-5A decreases mela-
noma cell proliferation and sensitizes them to BRAF
inhibitor-induced cell death [48].
WNT-5A regulates motility in prostate cancer cells as
well by promoting actin remodeling via Ca2?-CaMKII
signaling [146]. Prostate cancer tissues show increased
expression of WNT-5A [146, 168] promoting migration
and invasiveness [147]. WNT-5A signaling through ROR2
and FZD2 activates protein kinase D (PKD) and JNK to
induce Matrixmetalloprotease 1 (MMP1) expression via
JunD [147]. MMP1 expression is important for prostate
cancer cell invasiveness and bone metastasis [169]. Bone is
a major site for metastasis of various tumors including
prostate cancer. Prostate cancer cells show increased
migration towards bone marrow stromal cells which is
suppressed in the presence of WNT-5A siRNA-transfected
bone marrow stromal cells, suggesting that WNT-5A can
also function as a chemoattractant or homing factor for
prostate cancer cells [170]. The prostate cancer and bone
cross-talk also promotes prostate cancer cell proliferation.
WNT-5A expressed by bone marrow stromal cells induces
expression of BMP-6 in prostate cancer cells via a PKC-
NFjB pathway [171]. BMP-6, in turn, activates SMAD and
b-catenin signaling to promote proliferation in prostate
cancer cells [171]. Indeed, considerable nuclear b-catenin
staining is found in prostate cancer tissues [147]. This
signaling mechanism also explains the development of
castration-resistant prostate cancer phenotype. Prostate
cancer cells require androgens for their growth and as such
androgen restriction is first-line therapy for prostate cancer
patients. With time, considerable subsets of patients
develop androgen-resistant prostate cancer. WNT-5A
induced BMP-6, thus contributes to the proliferation of
prostate cancer cells in the absence of androgens [171].
Studies have suggested a broader function for WNT-5A
in cancer than just cell growth and invasion. For instance, it
can relay immunomodulatory and proangiogenic functions
or modulate cell survival. WNT-5A induces the release of
IL-6, MMP2, and vascular endothelial growth factor
(VEGF) containing exosomes from melanoma cells in a
Table 1 WNT-5A in cancer
Cancer Expression Signaling Effector(s) Consequence(s)





Invasion, metastasis [146, 147, 169]
Proliferation [171]
Non-melanoma Upregulated [149] ? ? Invasion [149]







VEGF, IL-6, MMP2 [172]
LDH5 [174]














NSCLC Upregulated [161, 162] PKC-AKT [164] BCL-2 [164] Survival [164]
Acute ATL Upregulated [151] ? RANK [151] Osteolytic lesions [151]
Colorectala Upregulated [184] ? ? Invasion [184]
Thyroidc Upregulated [143]c Ca2?-CaMKII [143] b-Catenin [143]c (Reduced) proliferation, migration [143]c




Colorectalb Downregulated [144] ? b-Catenin [179] Proliferation, migration [144, 179, 183]
AML/ALL Downregulated [145] ? ? B cell proliferation [145]
ESCC Downregulated [156] ? b-Catenin [156] Proliferation, migration [156]
? unknown
a Early recurrence or metastatic
b Lymph-node negative or Dukes’ B
c Despite overexpression, WNT-5A is suggested to function as tumor suppressor in thyroid carcinoma, reduces b-catenin activity and prolif-
eration and migration
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Ca2?- and CDC42-dependent process that requires
cytoskeletal reorganization [172]. Co-culture of WNT-5A-
deficient melanoma cells with endothelial cells suppresses
endothelial cell branching, whereas treatment of endothe-
lial cells with exosomes isolated from WNT-5A-treated
melanoma cells induces angiogenesis highlighting a
proangiogenic role for WNT-5A [172]. WNT-5A also
suppresses expression of tumor-associated antigens in
melanoma cells via activation of PKC and STAT3. This
leads to impaired cytotoxic T-cell clearance of tumor cells
[173]. Interestingly, WNT-5A can drive metabolic repro-
gramming in cancer cells by inducing lactate
dehydrogenase 5 (LDH5) leading to an increase in anaer-
obic glycolysis [174]. The serum level of LDH is an
important predictor of prognosis and treatment response in
melanoma patients [175]. WNT-5A and LDH5 expression
levels positively correlate in melanoma patient tissue
samples [174]. This is particularly important as strong
staining of both WNT5A and LDH5 is linked with reduced
disease-free survival in melanoma patients [148, 174].
Contrary to its effects in melanoma cells, WNT-5A
increases oxidative phosphorylation rates in breast cancer
cells demonstrating a context-dependent function of WNT-
5A that can also explain its tumor-promoter and tumor-
suppressor roles [174].
What drives increased expression of WNT-5A in cancer
cells? A study has found that microRNA-26a expression is
reduced in prostate cancer cells [176]. miR-26a suppresses
WNT-5A and forced expression of miR-26a attenuates cell
proliferation, metastasis, and EMT, and induced G1 phase
arrest suppressing WNT-5A expression and inhibiting
prostate cancer progression [176]. Epigenetic mechanisms
could also participate in the aberrant expression of WNT-
5A in cancer cells. Hypomethylation of the WNT-5A
promoter in prostate cancer cells accounts for the increased
transcription of WNT-5A in these cells [177]. In another
scenario, reduced expression of WNT-5A antagonists such
as Klotho might contribute to increased availability and
signaling of WNT-5A in cancer cells [178]. Expressions of
Klotho and WNT-5A are inversely correlated in melanoma
tissues, whereas the presence of Klotho suppressed mela-
noma cell invasion [178].
In addition to tumor-promoting activity, WNT-5A also
functions as tumor suppressor in few cancer types. In
colorectal cancer (CRC), loss of WNT-5A is frequently
observed and associated with poor prognosis and survival
[144]. In line with this, methylation of the WNT-5A pro-
moter is observed in metastatic CRC cell lines explaining
low abundance of WNT-5A in CRC [179, 180]. Promoter
methylation of WNT-5A is associated with distinct tumor
subtypes in colorectal cancer [181, 182]. Treatment of
CRC cells with Genistein, a soy flavonone and tyrosine
kinase inhibitor with protective activity in CRC, reduces
WNT-5A promoter methylation thereby increasing WNT-
5A gene expression and inhibiting cell proliferation [183].
WNT-5A also attenuates migration of colon cancer cell
lines [144]. As activated WNT/b-catenin is associated with
CRC, ectopic expression of WNT5A resulted in substantial
inhibition of tumor cell clonogenicity of CRC cells, with
downregulation of intracellular b-catenin protein level and
concomitant decrease in b-catenin activity [179].
In a contrasting study, increased WNT-5A expression is
associated with poor prognosis in CRC patients and WNT-
5A promoted directional cell migration and invasion in
CRC cells. However, increased expression of WNT-5A is
not sufficient to augment malignancy or metastasis in APC-
driven intestinal tumor model [184] suggesting that addi-
tional, not yet understood, mechanisms govern WNT-5A
activity at different stages of cancer pathogenesis. While
further studies are required to elucidate a clear role of
WNT-5A in CRC, it is tempting to speculate that WNT-5A
acts as a tumor suppressor in b-catenin-dependent stages of
CRC progression.
Loss of WNT-5A is observed in primary invasive breast
cancers and is associated with higher histological grade and
rapid appearance of distant metastases leading to shorter
recurrence-free survival in these patients [141, 142]. The
low abundance of WNT-5A in breast cancer cells could be
attributed to epigenetic silencing of the WNT-5A promoter.
Elevated expression of protein inhibitor of activated STAT
1 (PIAS1) is found in breast cancer tissues and it has been
shown to associate with methylated regions of WNT-5A
promoter in breast cancer cells [185]. PIAS1, a transcrip-
tional regulator, is known to recruit DNA
methyltransferases (DNMTs) thereby regulating promoter
methylation. Of note, knock-down of PIAS1 coincides with
reduced methylation and increased acetylation of the
WNT-5A promoter indicating gene activation with a sub-
sequent increase in WNT-5A expression. It leads to
reduction in the number of tumor-initiating cells and
attenuates breast cancer growth in vivo suggesting that
epigenetic silencing of WNT-5A via PIAS1 is an important
feature in breast cancer [185]. Additionally, the low WNT-
5A expression could also be due to posttranslational sup-
pression of WNT-5A mRNA in breast cancer cells by HuR
proteins. Of note, HuR expression is highly augmented in
invasive breast cancer cells [36]. Further, miRNA-374a is
highly increased in breast cancer tissues and is associated
with poor metastasis-free survival [186]. miRNA-374a
promotes EMT and metastasis in breast cancer cells both
in vivo and in vitro via targeted downregulation of negative
regulators of WNT/b-catenin signaling such as WNT-5A
[186].
The tumor suppressive function could also be attributed
to adhesion promoting function of WNT-5A in certain cell
types. WNT-5A could regulate mammary epithelial cell
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adhesion by phosphorylating Discoidin domain receptor 1
and activating its interaction with collagen thereby nega-
tively regulating cell migration [187]. Similarly, WNT-5A
stimulation of breast epithelial cells increases adhesion by
inducing CK1a-dependent phosphorylation of b-catenin
which, in turn, promotes E-cadherin-b-catenin association
[188]. This stabilizes adheres junctions and attenuates b-
catenin transcriptional function [188]. WNT-5A activates
CDC42 in various cell types including breast cancer cells.
A study found that WNT-5A-activated CDC42 limits
ERK1/2 activation and subsequent MMP9 expression. This
is suggested to restrain cell migration and invasiveness in
breast cancer [189]. In agreement with these observations,
small WNT-5A-derived peptides could increase adhesion
and decrease metastasis and invasion of breast cancer cells
both in vitro and in vivo [190, 191].
In contrast to the tumor-suppressor function of WNT-5A
in breast cancer, studies have also suggested a cell migra-
tion-promoting role for WNT-5A. In a breast cancer cell line
MDA-MB-231 which expresses very low endogenous
WNT-5A, stimulation with WNT-5A activated a DVL2- and
Daam1-dependent RhoA signaling inducing cell migration
[110], whereas in another breast cancer cell line with high
endogenous WNT-5A levels (MCF-7), WNT-5A can pro-
mote cell migration via a DVL2-Rab35-Rac1-dependent and
RhoA-independent signaling [109]. In a contrasting study
using MCF-7 cell line, WNT-5A attenuated filopodia for-
mation and cell migration via activation of cAMP-regulated
phosphoprotein of 32 kDa (DARPP-32) and CREB [192].
Interestingly, macrophages associated with primary breast
cancer tissues have been shown to express WNT-5A [193].
The co-culture of MCF-7 with macrophages promotes
WNT-5A expression in macrophages and invasiveness of
MCF-7, a feature which was also recapitulated by direct
stimulation of MCF-7 with recombinant WNT-5A [193].
Similarly, microglia, the resident brain macrophages, have
been shown to enhance breast cancer cell (MCF-7) invasion
in a WNT-dependent manner [194]. The study showed
microglia transporting breast cancer cells into the brain tis-
sue [194]. Of note, WNT-5A has been shown to induce
proliferation and invasion of microglia [59]. While the pro-
cell migratory effects of WNT-5A in breast cancer require
further studies, it is quite possible that WNT-5A regulates
breast cancer metastasis depending on the tumor-microen-
vironment communication.
The opposing roles for WNT-5A in cancer are intriguing
and are matter of intense investigation. As WNT-5A
antagonizes WNT/b-catenin signaling, it is tempting to
speculate that it functions as tumor suppressor in WNT/b-
catenin-dependent cancers provided it activates the down-
stream cascade involved in this antagonism. The pro-tumor
activity might be attributed to the cell migratory, prolifer-
ative. and prosurvival effects of WNT-5A. Moreover, the
differential role of WNT-5A could also be due to different
properties of recently characterized WNT-5A isoforms.
WNT-5A promoter generates two identical transcripts uti-
lizing alternative transcription start sites—WNT-5A-L and
WNT-5A-S [24–26]. While WNT-5AL inhibits tumor
growth, WNT-5AS promotes it. Expression of these two
isoforms is altered in breast cancer, cervix carcinoma, and
aggressive neuroblastomas where WNT-5A-L is down-
regulated and WNT-5A-S is most abundantly expressed
[25]. Thus, not only the downstream signaling but also the
abundance of specific isoforms can contribute to the dif-
ferential effects of WNT-5A in cancer. Thus, the
downstream effects of WNT-5A are highly context
dependent and the differential signaling mechanisms it
engages may account for the opposing functions of WNT-
5A in cancer.
WNT-5A as a therapeutic target
While we still await a clear understanding of WNT-5A
biology, development of certain WNT-5A mimicking
molecules and their beneficial effects in animal models of
diseases raise hopes for therapeutic targeting of WNT-5A
for curing deadly diseases. Foxy5 is a WNT5A derived
N-formylated hexapeptide which mimics tumor suppres-
sive effects of WNT5A on breast cancer both in vitro [190,
191] and in vivo [191]. The presence of Foxy5 has anti-
migratory effects on breast cancer cell line [190, 191] and
administration of Foxy5 has been shown to prevent lung
and liver metastases in a mouse model of breast cancer
[191]. The substitution of N-terminal formyl group of
Foxy5 with a t-butoxycarbonyl group (t-boc) reversed its
function turning Foxy5 into WNT-5A antagonist, termed
Box5 [195]. Box5 antagonizes WNT-5A-induced mela-
noma cell invasion [195] and prevents b-amyloid peptide-
induced WNT-5A-dependent inflammation and neurotoxi-
city in mouse cortical cultures [136].
Likewise, UM206, a oligopeptide with high homology
to WNT-5A, functions as a FZD1/FZD2 antagonist with
therapeutic benefit in reducing cardiac remodeling an ani-
mal model of myocardial infarction [196]. Although the
effects of UM206 cannot be attributed specifically to
WNT-5A as the peptide also blocks signaling induced by
WNT-3A, WNT-5A is known to regulate fibroblast pro-
liferation, migration, and activation leading to matrix
remodeling [16, 103].
Conclusion
WNT-5A is a pleotropic growth factor with wide-ranging
effects in different cells and tissues, regulating key func-
tions throughout the human life span. While it is
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indispensable for proper embryonic development, it is
equally critical for maintenance of tissue homeostasis in
adult life. Simultaneously, derailed WNT-5A signaling
results in various pathological disorders in humans.
Understanding the mechanisms involved in the mainte-
nance of WNT-5A homeostasis such as its inducers and
signaling partners, both positive and negative modulators,
is key for therapeutic targeting of this important WNT in
various diseases.
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